文章名稱引用次數(shù)

• KRAS-Mutant non-small cell lung cancer: From biology to therapy46
• Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study31
• Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE- KEYNOTE- and KEYNOTE-042 studies27
• Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis25
• Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis22
• Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK1120
• Radiomics signature: A potential and incremental predictor for EGFR mutation status in NSCLC patients, comparison with CT morphology19
• Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)17
• Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer17
• Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis16